Kura Oncology, Inc. (KURA): Price and Financial Metrics

Kura Oncology, Inc. (KURA): $13.89

0.07 (+0.51%)

POWR Rating

Component Grades













Add KURA to Watchlist
Sign Up

Industry: Biotech



in industry

KURA Stock Price Chart Interactive Chart >

Price chart for KURA

KURA Price/Volume Stats

Current price $13.89 52-week high $19.93
Prev. close $13.82 52-week low $10.41
Day low $13.21 Volume 492,600
Day high $14.04 Avg. volume 748,524
50-day MA $13.63 Dividend yield N/A
200-day MA $14.56 Market Cap 929.20M

Kura Oncology, Inc. (KURA) Company Bio

Kura Oncology is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines for the treatment of solid tumors and blood cancers. The company was founded in 2014 and is based in La Jolla, California.

KURA Latest News Stream

Event/Time News Detail
Loading, please wait...

KURA Latest Social Stream

Loading social stream, please wait...

View Full KURA Social Stream

Latest KURA News From Around the Web

Below are the latest news stories about KURA ONCOLOGY INC that investors may wish to consider to help them evaluate KURA as an investment opportunity.

Kura Oncology Announces FDA Clearance of IND Application for KO-2806, a Next-Generation Farnesyl Transferase Inhibitor

SAN DIEGO, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the clearance by the U.S. Food and Drug Administration (FDA) of the Investigational New Drug (IND) application for KO-2806, the Company's next-generation farnesyl transferase inhibitor (FTI), for the treatment of advanced solid tumors. The Company intends to evaluate safet

Yahoo | January 24, 2023

An Intrinsic Calculation For Kura Oncology, Inc. (NASDAQ:KURA) Suggests It's 48% Undervalued

Today we will run through one way of estimating the intrinsic value of Kura Oncology, Inc. ( NASDAQ:KURA ) by...

Yahoo | January 6, 2023

Kura Oncology Shares Fall After Updated Ziftomenib Data At ASH Meeting

Kura Oncology Inc (NASDAQ: KURA) announced updated clinical data from the KOMET-001 Phase 1/2 trial of ziftomenib in patients with relapsed/refractory acute myeloid leukemia (AML). Ziftomenib demonstrated optimal clinical benefit at 600 mg with a 30% CR rate (6/20) in patients with NPM1-mutant AML, compared to 17% (1/6) at 200 mg. Notably, four NPM1-mutant patients who achieved a CR at 600 mg had IDH and/or FLT3 co-mutations. Related: Kura Oncology Reports Preliminary Proof Of Mechanism Data Fro

Yahoo | December 12, 2022

Kura Oncology Presents Updated Clinical Data from KOMET-001 Trial of Menin Inhibitor Ziftomenib at American Society of Hematology Annual Meeting

– 30% CR rate at 600 mg in 20 patients with relapsed/refractory NPM1-mutant AML –– Low frequency of differentiation syndrome, including 5% rate (1/20) of ≥ Grade 3 among NPM1-mutant patients treated at 600 mg –– 600 mg determined as recommended Phase 2 dose for ziftomenib in NPM1-mutant AML following positive Type C meeting with FDA –– Company expects to dose first patient in Phase 2 registration-directed trial in NPM1-mutant AML in first quarter of 2023 –– Further clinical development of KTM2A-

Yahoo | December 10, 2022

Wall Street Analysts Believe Kura Oncology (KURA) Could Rally 111%: Here's is How to Trade

The consensus price target hints at an 110.5% upside potential for Kura Oncology (KURA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Yahoo | December 1, 2022

Read More 'KURA' Stories Here

KURA Price Returns

1-mo 15.27%
3-mo -3.94%
6-mo -10.33%
1-year 4.04%
3-year 18.82%
5-year -29.85%
YTD 11.93%
2022 -11.36%
2021 -57.13%
2020 137.53%
2019 -2.07%
2018 -8.24%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.7055 seconds.